Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Response To Ruxolitinib In Patients With Intermediate-1, Intermediate-2 and High-Risk Myelofibrosis: Interim Results Of The UK Robust Trial

Claire N Harrison, DM, FRCP, FRCPath, Richard E Clark, MD, Joseph Chacko, Steven Knapper, DM BMBCh, John Yin, MD, Dragana Milojkovic, PhD, Mira Farquharson, FRCPath, MBChB, MRCP, Sahra Ali, FRCPath, FRCP, BM, MRCP, MRCPath, Mamta K Garg, MD, FRCP, FRCPath, Christopher Andrews, PhD, Cstat, CSci, Susan M Graham, PhD, Adam J. Mead, M.D., Ph.D.

Blood (2013) 122 (21): 2826.

https://doi.org/10.1182/blood.V122.21.2826.2826

Published: 2013

Journal Articles

Azacitidine Induces Expansion of Regulatory T Cells and Tumour Specific CD8+ T Lymphocytes After Allogeneic Stem Cell Transplantation: A Strategy for Epigenetic Manipulation of a Graft-Versus-Leukemia Response

Mike Dennis, Oliver Goodyear, Justin Loke, Nadiria Jilani, Shamyla Siddique, Gordon Ryan, Rehela Khanum, John Snowden, Michael Griffiths, PhD, Nigel H. Russell, MD, John Yin, MD, Charles Crawley, MD, Gordon Cook, MD, PhD, Paresh Vyas, DPhil, FRCP, FRCPath, Paul AH Moss, MD PhD, Ram Malladi, Charles F. Craddock, BM, MRCP, MRCPath

Blood (2011) 118 (21): 324.

https://doi.org/10.1182/blood.V118.21.324.324

Published: 2011

Journal Articles

Reduced Intensity Allogeneic Tranplants Are Well Tolerated In Patients Over the Age of 60: Identification of Factors Predicting Overall Survival

Emmanouil Nikolousis, Sandeep Nagra, Janice Ward, Fiona L Dignan, MD, Bronwen E. Shaw, PhD, MRCP, FRCPath, Simon Littlewood, Jenny Byrne, MD, PhD, Maria Helena Gilleece, MD, FRCPath, MB, BSc, FRCP, Eleni Tholouli, Fiona Clark, Mark Cook, Premini Mahendra, MD, Gordon Cook, MD, John Yin, MD, Nigel H. Russell, MD, Charles Craddock

Blood (2010) 116 (21): 2361.

https://doi.org/10.1182/blood.V116.21.2361.2361

Published: 2010

Journal Articles

The Addition of Gemtuzumab Ozogamicin to Low Dose Ara-C Improves Remission Rates but Not Survival: Results of the UK LRF AML14 and NCRI AML16 “Pick a Winner” Comparison

Alan Burnett, Robert Hills, MA, MSc, DPhil, Ann Elizabeth Hunter, MBBS, FRCP, FRCPath, Donald Milligan, MD, FRCP, FRCPath, William J. Kell, MD, MB, Keith Wheatley, John Yin, MD, Mary Frances McMullin, MD, Helen Dignum, David Bowen, Nigel H. Russell, MD

Blood (2010) 116 (21): 18.

https://doi.org/10.1182/blood.V116.21.18.18

Published: 2010

Journal Articles

A Comparison of Conditioning Regimens with or without Alemtuzumab for Sibling RIC Transplants for AML: Study from the British Society for Blood and Marrow Transplantation.

Ram K. Malladi, MD, Andrew J. Peniket, MD, Timothy James Littlewood, MD, Keiren E. Towlson, MSc SRN, Rachel Pearce, John Yin, MD, Jamie D. Cavanagh, MD, Charles Craddock, MD, Kim H. Orchard, MD, David I. Marks, MD

Blood (2006) 108 (11): 3002.

https://doi.org/10.1182/blood.V108.11.3002.3002

Published: 2006

NARROW

Response To Ruxolitinib In Patients With Intermediate-1, Intermediate-2 and High-Risk Myelofibrosis: Interim Results Of The UK Robust Trial

Azacitidine Induces Expansion of Regulatory T Cells and Tumour Specific CD8+ T Lymphocytes After Allogeneic Stem Cell Transplantation: A Strategy for Epigenetic Manipulation of a Graft-Versus-Leukemia Response

Reduced Intensity Allogeneic Tranplants Are Well Tolerated In Patients Over the Age of 60: Identification of Factors Predicting Overall Survival

The Addition of Gemtuzumab Ozogamicin to Low Dose Ara-C Improves Remission Rates but Not Survival: Results of the UK LRF AML14 and NCRI AML16 “Pick a Winner” Comparison

A Comparison of Conditioning Regimens with or without Alemtuzumab for Sibling RIC Transplants for AML: Study from the British Society for Blood and Marrow Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Response To Ruxolitinib In Patients With Intermediate-1, Intermediate-2 and High-Risk Myelofibrosis: Interim Results Of The UK Robust Trial

Azacitidine Induces Expansion of Regulatory T Cells and Tumour Specific CD8+ T Lymphocytes After Allogeneic Stem Cell Transplantation: A Strategy for Epigenetic Manipulation of a Graft-Versus-Leukemia Response

Reduced Intensity Allogeneic Tranplants Are Well Tolerated In Patients Over the Age of 60: Identification of Factors Predicting Overall Survival

The Addition of Gemtuzumab Ozogamicin to Low Dose Ara-C Improves Remission Rates but Not Survival: Results of the UK LRF AML14 and NCRI AML16 “Pick a Winner” Comparison

A Comparison of Conditioning Regimens with or without Alemtuzumab for Sibling RIC Transplants for AML: Study from the British Society for Blood and Marrow Transplantation.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only